Director/PDMR Shareholding

MaxCyte, Inc.
31 January 2024
 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Exercise of options and PDMR dealing

 

ROCKVILLE, MD, January 31, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, announces that on 26 January 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 5,000 new shares of Common Stock were issued pursuant to the Company's existing block admission facility and were sold by John Johnston at a price range between $5.040 and $5.145 per Common Stock ("Sale"). The sold shares represent approximately 1.7% of John Johnston's total equity and option holdings in the Company's stock capital, respectively.

 

Following the Exercise and Sale, John Johnston holds 120,583 shares of Common Stock representing 0.1% of the issued stock capital of the Company. Following the Exercise, John Johnston holds a further 172,217 options over Common Stock.

 

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by John Johnston on 28 March 2023 relating solely to the sale of shares acquired from exercise of options that expire on 4 January 2029.

 

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

+1 415-937-5400

ir@maxcyte.com

 

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

John Johnston

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Exercise of Options over common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$2.142

5,000







d)

 

Aggregated information




- Aggregated volume

5,000



- Price

$2.142



e)

 

Date of the transaction

 

 

26 January 2024

f)

 

Place of the transaction

 

 

US Stock Exchange, Nasdaq

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

John Johnston

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Sale of common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$5.0400

8




$5.0800

185




$5.0950

95




$5.1000

291




$5.1050

203




$5.1100

667




$5.1150

1679




$5.1200

565




$5.1250

645




$5.1400

565




$5.1450

97







d)

 

Aggregated information




- Aggregated volume

5,000



- Price

$5.1165



e)

 

Date of the transaction

 

 

26 January 2024

f)

 

Place of the transaction

 

 

US Stock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100